跳至主要内容
临床试验/NCT03029104
NCT03029104终止2 期

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

Cxlusa18 个研究点 分布在 1 个国家目标入组 2,228 人开始时间: 2016年12月21日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
发起方
Cxlusa
入组人数
2,228
试验地点
18
主要终点
Change From Baseline in Corrected Distance Visual Acuity (CDVA)

研究概览

简要总结

This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.

详细描述

This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all patients receive treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Visual acuity will be evaluated by an observer who is masked as to the treatment protocol to which study subjects have been assigned.

入排标准

年龄范围
8 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A diagnosis of at least one of the following conditions:
  • Keratoconus
  • Forme fruste keratoconus
  • Post-LASIK ectasia
  • Pellucid marginal degeneration
  • Forme fruste pellucid marginal degeneration
  • Diurnal fluctuation post-radial keratotomy
  • Terrien's marginal degeneration

排除标准

  • Corneal thickness < 375 microns measured by ultrasound or Pentacam.
  • Contraindications or hypersensitivities to any study medications or their components.
  • Pregnancy or breastfeeding.
  • Any history of herpes simplex corneal disease in an eye to be treated.
  • Nystagmus or any other condition that would, in the judgement of the investigator, prevent a steady gaze during the treatment.
  • Inability to cooperate with diagnostic tests.
  • Enrollment in another ophthalmic clinical trial.

结局指标

主要结局

Change From Baseline in Corrected Distance Visual Acuity (CDVA)

时间窗: Baseline and 6 and 12 months

Changes in CDVA are reported as the value at 6 and 12 months minus the value at baseline

次要结局

  • Change From Baseline in Uncorrected Distance Visual Acuity (UCVA)(Baseline and 6 and 12 months)
  • Change From Baseline in Maximum Keratometry (KMax)(Baseline and 6 and 12 months)

研究者

发起方
Cxlusa
申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验